Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a tertiary hospital

Authors : Aysun Taşdemir Ari, Mustafa Berhuni, Gizem Gürbostan Soysal, Nesime Setge Tiskaoğlu

Pages : 13-16

Doi:10.32322/jhsm.1367325

View : 74 | Download : 72

Publication Date : 2024-01-15

Article Type : Research Paper

Abstract :Aims: To investigate the incidence of acute endophthalmitis after intravitreal bevacizumab injections. Methods: Patients who received treatment with intravitreal bevacizumab (1.25 mg/0.05 ml) injections for various indications between November 2020 and March 2022 were included in this retrospective study. The patients were followed up for 4 weeks after the injection in terms of acute endophthalmitis symptoms and signs. Results: Acute endophthalmitis developed in 1 patient after 4593 intravitreal bevacizumab injections were administered to 1427 eyes of 1026 patients, and the incidence was found to be 0.0217%. The patient who developed acute endophthalmitis underwent pars plana vitrectomy and after 3 months, a significant improvement in visual acuity was observed. Conclusion: Development of endophthalmitis postoperatively was found to be moderately low after intravitreal bevacizumab injection. It was concluded that following asepsis rules and optimal bevacizumab preparation conditions could further reduce this.
Keywords : Bevacizumab, Intravitreal injections, Endophthalmitis, Complications